Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

14.86
-0.1600-1.07%
Post-market: 15.100.2375+1.60%18:32 EDT
Volume:1.67M
Turnover:24.85M
Market Cap:1.77B
PE:-14.29
High:15.21
Open:14.94
Low:14.44
Close:15.02
Loading ...

Arcutis Biotherapeutics (ARQT) Gets a Buy from Guggenheim

TIPRANKS
·
21 Jul

Jefferies Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
21 Jul

Patrick Burnett, Officer, Reports Disposal of Common Shares of Arcutis Biotherapeutics Inc

Reuters
·
15 Jul

Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
08 Jul

BRIEF-Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Jul

Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
03 Jul

Arcutis Biotherapeutics' Zoryve Cream Receives Recommendation From American Academy of Dermatology

MT Newswires Live
·
26 Jun

Arcutis Biotherapeutics Inc - Zoryve Recommended for Efficacy, Safety, and Tolerability

THOMSON REUTERS
·
26 Jun

Arcutis’ Zoryve® (Roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

THOMSON REUTERS
·
26 Jun

Director Howard G. Welgus Reports Disposal of Common Shares in Arcutis Biotherapeutics Inc

Reuters
·
21 Jun

Director Makes Bold Move with Arcutis Biotherapeutics Stock Purchase

TIPRANKS
·
18 Jun

Director Patrick J. Heron Reports Acquisition of Common Shares in Arcutis Biotherapeutics Inc

Reuters
·
18 Jun

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting

TIPRANKS
·
18 Jun

Arcutis Biotherapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
18 Jun

Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT

TIPRANKS
·
10 Jun

Arcutis Enrolls First Child in Integument-Infant Evaluating Zoryve® (Roflumilast) Cream 0.05% in Infants With Atopic Dermatitis

THOMSON REUTERS
·
10 Jun

Arcutis Biotherapeutics Launches Phase 2 Study for ZORYVE Cream in Infants with Atopic Dermatitis

Reuters
·
10 Jun

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jun

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
07 Jun

Patrick J. Heron, Director, Reports Acquisition of Arcutis Biotherapeutics Inc. Common Shares

Reuters
·
06 Jun